Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, Fukuda K, Abe M, Ito S
Second Department of Internal Medicine, Tokushima University School of Medicine, Japan.
J Hypertens. 1996 Dec;14(12):1403-8. doi: 10.1097/00004872-199612000-00003.
To investigate the relationship between the angiotensin converting enzyme (ACE) gene polymorphism and the effects of the ACE inhibitor enalapril on left ventricular hypertrophy and impaired diastolic filling.
Enalapril (5-10 mg/day) was administered for 12 months to 60 previously untreated patients with essential hypertension. M-mode and pulsed Doppler echocardiography were performed before and after treatment, and changes in various parameters after treatment with enalapril were examined. ACE gene polymorphism was examined by the polymerase chain reaction method and the patients were classified as having the 190 bp deletion homozygous (DD) genotype, the 490 bp insertion homozygous (II) genotype or the 490 bp insertion 190 bp deletion heterozygous (ID) genotype.
The DD genotype was observed in 10 patients (17%), the ID genotype in 24 patients (40%) and the II genotype in 26 patients (43%). Plasma ACE activity before treatment with enalapril was significantly higher in seven patients with DD genotype than it was in 18 patients with ID genotype and in 14 patients with II genotype. In all of the 60 patients, the left ventricular mass index, the peak atrial systolic velocity:early diastolic velocity ratio and the deceleration time from the peak of the early diastolic wave to the baseline in transmitral flow velocity were decreased significantly after treatment with enalapril. The changes in left ventricular mass index and atrial systolic velocity:early diastolic velocity ratio after enalapril administration were significantly greater in the DD genotype group than they were in the other two genotype groups.
Enalapril-induced regression of left ventricular hypertrophy and improvement in left ventricular impaired diastolic filling were significantly greater in the DD genotype group than they were in the ID and II genotype groups, suggesting that the circulating and tissue renin-angiotensin systems, particularly the former system, are most active in hypertensive patients with the DD genotype.
探讨血管紧张素转换酶(ACE)基因多态性与ACE抑制剂依那普利对左心室肥厚及舒张功能障碍影响之间的关系。
对60例未经治疗的原发性高血压患者给予依那普利(5 - 10毫克/天)治疗12个月。治疗前后进行M型和脉冲多普勒超声心动图检查,观察依那普利治疗后各项参数的变化。采用聚合酶链反应法检测ACE基因多态性,将患者分为190 bp缺失纯合子(DD)基因型、490 bp插入纯合子(II)基因型或490 bp插入/190 bp缺失杂合子(ID)基因型。
10例患者(17%)为DD基因型,24例患者(40%)为ID基因型,26例患者(43%)为II基因型。依那普利治疗前,7例DD基因型患者的血浆ACE活性显著高于18例ID基因型患者和14例II基因型患者。在所有60例患者中,依那普利治疗后左心室质量指数、心房收缩期峰值速度与舒张早期速度比值以及二尖瓣血流速度从舒张早期波峰到基线的减速时间均显著降低。依那普利给药后,DD基因型组左心室质量指数和心房收缩期速度与舒张早期速度比值的变化显著大于其他两个基因型组。
依那普利诱导的左心室肥厚消退及左心室舒张功能障碍改善在DD基因型组中显著大于ID和II基因型组,提示循环和组织肾素 - 血管紧张素系统,尤其是前者,在DD基因型高血压患者中最为活跃。